Key facts
- Iris Medicine’s last known valuation is $4.4M (May 2020).
- It has raised $400K; the latest was Later Stage VC in Jan 2025.
- Notable investors include Venrock, Altitude Life Science Ventures, Berkeley Catalyst Fund Management, PsyMed Ventures, UCB Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Iris Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Iris Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Iris Medicine
Developer of a ribonucleic acid therapeutics platform designed to treat genetic diseases. The company's platform leverages the cooperativity inherent in the RNAi machinery to selectively modulate ribonucleic acid transcripts harboring expanded, pathologic repeat sequences, enabling medical professionals to streamline the treatment of neurological diseases.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2019
- Employees
- 11
- Website
- irismedicine.com/
- Ownership
- Privately Held (backing)
Iris Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iris Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iris Medicine in its N-PORT filings yet. We sweep new filings monthly.